Determinants of daily insulin use in type 1 diabetes by Muis, Marian J. et al.
  
 University of Groningen
Determinants of daily insulin use in type 1 diabetes
Muis, Marian J.; Bots, Michiel L.; Bilo, Henk J. G.; Hoogma, Roel P. L. M.; Hoekstra, Joost B.
L.; Grobbee, Diederick E.; Stolk, Ronald P.
Published in:
JOURNAL OF DIABETES AND ITS COMPLICATIONS
DOI:
10.1016/j.jdiacomp.2005.08.006
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2006
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Muis, M. J., Bots, M. L., Bilo, H. J. G., Hoogma, R. P. L. M., Hoekstra, J. B. L., Grobbee, D. E., & Stolk, R.
P. (2006). Determinants of daily insulin use in type 1 diabetes. JOURNAL OF DIABETES AND ITS
COMPLICATIONS, 20(6), 356-360. https://doi.org/10.1016/j.jdiacomp.2005.08.006
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Journal of Diabetes and Its CompDeterminants of daily insulin use in Type 1 diabetes
Marian J. Muisa,b, Michiel L. Botsa, Henk J.G. Biloc, Roel P.L.M. Hoogmad,
Joost B.L. Hoekstrae, Diederick E. Grobbeea, Ronald P. Stolka,T
aJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
bDepartment of Internal Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
cIsala Clinics, Zwolle, The Netherlands
dGroene Hart Hospital, Gouda, The Netherlands
eAcademic Medical Center, Amsterdam, The Netherlands
Received 26 August 2004; received in revised form 4 April 2005; accepted 16 August 2005
Abstract
Objective: Insulin need for a given degree of glucose control varies markedly among individuals. We examined which factors determine
daily insulin use in patients with Type 1 diabetes. Methods: A cross-sectional study was performed in 416 patients. Clinical parameters,
medication use, physical activity, smoking, alcohol consumption, and laboratory parameters were determined. Results: Body mass index and
waist circumference were positively related to daily insulin use (2.3 U/kg/m2, 95% CI=1.9–2.7 and 0.8 U/cm, 95% CI=0.6–0.9, adjusted for
age and sex). Age, female sex, and duration of diabetes were inversely related to daily insulin dose. There was an increase of 3.6 U of insulin
per mmol/l triglycerides (95% CI=1.04–6.2) and a decrease of 5.9 U of insulin per mmol/l high-density lipoprotein cholesterol (95%
CI=10.0 to 1.8), adjusted for age, sex, and weight. For blood pressure-lowering drugs, the strongest relation was found for thiazide
diuretics (difference of 7.1 U insulin/day, 95% CI=0.2–14.2, adjusted for age, sex, and weight). The use of an insulin pump and physical
activity were related to lower daily insulin need: 8.7 U/day (95% CI=11.8 to 5.5) and 1.7 U/day per activity score unit (95% CI=3.2
to 0.2), respectively, adjusted for age, sex, and weight. Smoking was related to an increased need of 5.3 U/day (95% CI=1.5–9.0), adjusted
for age, sex, and weight. Conclusions: Our results show that components of the metabolic syndrome are positively related to daily insulin
use. Also, decreased physical activity, smoking, and the use of blood pressure-lowering drugs, which influence insulin sensitivity, are
associated with an increased insulin need. These findings suggest that the presence of insulin resistance in Type 1 diabetes or bdouble
diabetesQ plays a key role in determining daily insulin need.
D 2006 Elsevier Inc. All rights reserved.
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The importance of glucose control in diabetes mellitus is
firmly established. Since the Diabetes Control and Compli-
cations Trial (DCCT) in Type 1 diabetes and the UK
Prospective Diabetes Study (UKPDS) in Type 2 diabetes
have shown that long-term diabetic complications are
reduced by improved glycemic control (DCCT Research1056-8727/06/$ – see front matter D 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.jdiacomp.2005.08.006
T Corresponding author. Department of Epidemiology and Bioinfor-
matics University Medical Center Groningen, University of Groningen,
Hanzeplein 1 (9713 GZ), P.O. Box 30.001, 9700 RB Groningen, The
Netherlands. Tel.: +31 50 36 11879; fax: +31 50 36 11738.
E-mail address: r.p.stolk@epi.umcg.nl (R.P. Stolk).Group, 1993; UKPDS, 1998), the target value of hemoglobin
A1c (HbA1c) has been steadily lowered. As a result, insulin
treatment is intensified in Type 1 diabetes and insulin is used
in an increasing proportion of patients with Type 2 diabetes.
Apart from the clear beneficial effect of glucose-lowering,
insulin treatment results in weight gain, increases the risk of
acquiring hypoglycemia, and affects quality of life (DCCT
Research Group, 1993; Purnell et al., 1998). Moreover,
insulin is an anabolic hormone that in experimental studies
has shown to induce atherogenic effects (Muis, Bots,
Grobbee, & Stolk, in press; Vicent et al., 2003). Finally,
insulin treatment is expensive. In Type 1 diabetes, the
daily insulin need ranges markedly per individual from 0.4 tolications 20 (2006) 356–360
M.J. Muis et al. / Journal of Diabetes and Its Complications 20 (2006) 356–360 3570.85 U/kg/day (DCCT Research Group, 1993). Information
on the factors associated with insulin need may point to
possibilities for avoiding unnecessarily high insulin use.
In this light, we set out to investigate the determinants of
insulin use in individuals with Type 1 diabetes. In addition
to glucose control, body composition and physical activity
may also affect an individual’s insulin needs. In this study,
we examined lifestyle and other determinants of daily
insulin use.Table 1
General characteristics of the study population
Men Women
n 222 193
Age, years [mean (S.D.)] 45.8 (12.6) 40.3 (11.8)
Duration of diabetes, years [mean (S.D.)] 22.0 (12.2) 19.7 (10.6)
Family history of
diabetes–Types 1 and 2 (%)
31 30
BMI, kg/m2 [mean (S.D.)] 25.4 (3.5) 25.7 (3.8)
Obesity–BMIN27 kg/m2 (%) 28 32
Physical activitya [mean (S.D.)] 7.7 (1.1) 7.8 (1.1)
Alcohol use, g [mean (S.D.)] 16.8 (22.8) 7.0 (10.1)
SBP, mm Hg [mean (S.D.)] 144.7 (20.8) 133.9 (20.0)
DBP, mm Hg [mean (S.D.)] 83.0 (9.8) 80.9 (10.1)
HbA1c, % [mean (S.D.)] 7.9 (1.0) 7.9 (0.9)
Total cholesterol, mmol/l [mean (S.D.)] 4.9 (0.9) 5.1 (0.9)
TGs, mmol/l [mean (S.D.)] 1.0 (0.5) 1.0 (0.7)
HDL cholesterol, mmol/l [mean (S.D.)] 1.4 (0.4) 1.8 (0.4)




Proportion using h-blockers (%) 6 4
Proportion using thiazide diuretics (%) 4 6
Proportion using lipid-lowering drugs (%) 13 7






Pump use (%) 36 62
Current smoking (%) 29 19
SBP indicates systolic blood pressure; DBP, diastolic blood pressure.
a Measured by the modified Baecke questionnaire.2. Methods
2.1. Study population
A study was performed on 416 patients with Type 1
diabetes mellitus. Patients were recruited from the outpatient
clinics of the Isala Clinics (Zwolle, the Netherlands) and the
Groene Hart Hospital (Gouda, the Netherlands). Type 1
diabetes mellitus was defined as onset at an age younger
than 40 years in combination with insulin dependence from
diagnosis. The main inclusion criteria for enrollment were
age z18 years and duration of insulin treatment of at least
4 years. Of the 563 patients invited to participate in the
study, 416 responded. The 147 nonresponders did not
significantly differ from the responders in major determi-
nants (age, sex, duration of diabetes, and family history).
The medical ethics committees of the participating
institutions approved the study, and all patients gave their
written informed consent.
2.2. Clinical parameters
The patients were examined according to a standardized
protocol. Patients were asked to complete a questionnaire on
physical activity (estimated by the modified Baecke ques-
tionnaire; Pols et al., 1995) at home. Alcohol consumption,
smoking habits, use of medication including the actual daily
insulin dose, medical history including duration of diabetes
and diabetic complications, and family history for CVD,
hypertension, lipid disorders, and diabetes mellitus were
recorded during the visit at the research center. Blood
pressure was measured three times on the left arm with a
semiautomated device (Dynamap) in the supine position.
Height, weight, and waist circumference were measured and
body mass index (BMI; kg/m2) was calculated. The
averages of the latest available levels of glycosylated HbA1c
total serum cholesterol, high-density lipoprotein (HDL)
cholesterol, triglycerides (TGs), microalbumin, and creati-
nine from 2 years preceding study inclusion were obtained
from the patients’ medical files.
2.3. Physical activity
To assess daily physical activity (DPA), we used a
modified Baecke questionnaire for physical activity (Polset al., 1995). This questionnaire has been validated for the
Dutch population. The questionnaire consisted of scores in
work activities, sports activities, and other leisure time
activities that were added up to give the DPA score. Items
on each activity were questions with five possible ratings,
ranging from inactive to very active. Scores in sports and
other activities were calculated from type of activity and the
duration and period of the year in which the activity was
normally performed. All activities were classified according
to work, posture, and movements. An intensity code was
used to classify each type of activity. The higher the activity
score, the more active a patient was.
2.4. Data analysis
Data are summarized using means and standard devia-
tions or proportions. The relations between daily insulin use
and the different parameters were evaluated using univariate
and multivariate linear regression analyses. Adjustments
were made for differences in age, sex, and weight where
appropriate. Total daily insulin use was used as a continuous
variable in the analysis. The analyses were repeated for the
daily use of the specific types of insulin (short-acting
analogues, regular insulin, and intermediate-acting insulin).
In addition, we performed analyses separately for men and
women and for patients using an insulin pump. Data were
analyzed using SPSS 10.1 for Windows.
Fig. 1. Daily insulin dose by increasing age.
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The general characteristics of the 416 patients included in
the study are presented in Table 1. The mean age of the
patients was 43.2F12.5 years, and the mean duration of
their diabetes was 20.9F11.5 years. Of all the patients, 304
(73%) used short-acting analogues, 112 (27%) used regular
insulin, 217 (52%) used intermediate-acting insulin, and 199
(48%) were treated with an insulin pump. In the group of
patients who were treated with an insulin pump, 12% used
regular insulin whereas 88% used short-acting analogues.
The relations between clinical and biochemical parame-
ters and daily insulin use are presented in Table 2. As
expected, HbA1c levels were positively related to daily
insulin dose (2.2 U of insulin per %, 95% CI=0.3–4.1),
adjusted for sex and age. This relation was stronger in women
than in men (3.4 U of insulin per %, 95% CI=0.9–6.0
and 1.4 U of insulin per %, 95% CI=1.3–4.1, respectively).
Age was inversely related to daily insulin dose (decrease
of 0.4 U of insulin/year, 95% CI=0.5 to 0.2). Fig. 1Table 2





Age, years 0.4 (0.5 to 0.2)TT 0.4 (0.5 to 0.2)TT
Female sex 13.0 (16.7 to 9.2)TT 5.1 (8.6 to 1.7)TT










0.3 (4.2–4.8) 0.2 (3.6–3.9)
SBP, mm Hg 0.09 (0.008–0.2)T 0.02 (0.07–0.1)
DBP, mm Hg 0.1 (0.05–0.3) 0.02 (0.2–0.1)
HbA1c, % 2.2 (0.3–4.1)TT 1.5 (0.1–3.1)T
Total cholesterol,
mmol/l
1.3 (0.9–3.4) 0.5 (1.4–2.3)
TGs, mmol/l 7.0 (4.1–9.9)TT 3.6 (1.04–6.2)TT
HDL cholesterol,
mmol/l
9.8 (14.5 to 5.1)TT 5.9 (10.0 to 1.8)TT
Physical activity 1.1 (2.8–0.7) 1.7 (3.2 to 0.2)TT
Pump use 9.3 (13.0 to 5.6)TT 8.7 (11.8 to 5.5)TT
Current smoking 1.5 (2.8–5.8) 5.3 (1.5–9.0)TT
Alcohol use, g 0.03 (0.1–0.07) 0.01 (0.1–0.08)
Use of ACE
inhibitors
3.5 (1.8–8.7) 3.5 (1.0–8.0)
Use of calcium
blockers
12.7 (1.9–23.5)TT 8.8 (0.5–18.1)T
Use of h-blockers 8.3 (0.03–16.7)T 1.5 (5.9–8.8)
Use of thiazide
diuretics
10.4 (2.4–18.3)TT 7.1 (0.2–14.2)TT
Use of lipid-lowering
treatment
0.3 (6.1–6.7) 2.8 (8.3–2.7)
Values are expressed as linear regression coefficients, adjusted for sex and
age (if appropriate) and weight, with 95% CIs in parentheses, and reflect
changes in insulin units.
T Pb.10.
TT Pb.05.shows daily insulin dose by increasing age. TGs were
positively related to daily insulin use (increase of 7.0 U of
insulin per mmol/l, 95% CI=4.1–9.9), adjusted for sex and
age. Likewise, HDL cholesterol was inversely related to daily
insulin use (decrease of 9.8 U of insulin per mmol/l, 95%
CI=14.5 to 5.1). The associations for TG and HDL with
insulin attenuated when additional adjustment for weight was
performed but remained statistically significant (Table 2).
Physical activity was inversely related to insulin use, after
adjustment for age, sex, and weight (decrease of 1.7 U of
insulin per score unit, 95% CI=3.2 to 0.2).
Pump users needed less daily insulin than patients using
multiple injections (difference of 9.3 U of insulin/day,
95% CI=13.0 to 5.5). The analyses were repeated for
patients using an insulin pump. In this subgroup, results
were the same as those in the complete study population.
Similar relations were found when the analyses were
repeated separately for both sexes and for patients with
and those without a family history of diabetes.
The use of calcium-channel blockers, h-blockers, and
thiazide diuretics was related to higher total daily insulin
doses (respective difference of 12.7 U of insulin, 95%
CI=1.9–23.5; 8.3 U of insulin, 95% CI=0.03–16.7; and
10.4 U of insulin, 95% CI=2.4–18.3), adjusted for sex and
age. When weight was taken into account, the magnitude of
the association attenuated but remained statistically signifi-Table 3






Use of thiazide diuretics 15.3 (2.6–28.1)T 4.8 (4.4–14.1)
Use of calcium blockers 16.1 (3.6–28.5)T 3.7 (10.1–17.5)
Use of h-blockers 7.7 (1.8–17.2)P=.11 3.3 (14.5–8.0)
Use of ACE inhibitors 1.5 (4.1–7.1) 5.8 (1.5–13.1)
Values are expressed as linear regression coefficients, with 95% CIs in




A multivariate linear regression model of determinants of total daily
insulin use
Age, years 0.4 (0.6 to 0.3)T
Female sex 4.8 (8.5 to 1.1)T
Weight, kg 0.7 (0.6–0.8)T
HbA1c, % 1.2 (0.6–3.1)
TGs, mmol/l 3.4 (0.7–6.0)T
Current smoking, % 4.0 (0.02–7.9)P=.051
Physical activity score 1.4 (3.0–0.1)P=.069
Values are expressed as linear regression coefficients, with 95% CIs in
parentheses, and reflect changes in insulin units. R2=.41 (adjusted R2=.40).
T Pb.05.
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sive drugs with daily insulin use was more pronounced in
patients with a BMI V25.2 (median; Table 3). The relations
of clinical and biochemical parameters and daily doses of
the specific types of insulin were in magnitude similar to the
relations found for these parameters and the total daily
insulin dose. Table 4 presents the results of a multivariate
linear regression model built with the several determinants
of total daily insulin dose. To evaluate as to which extent
daily insulin use is explained by these factors, we estimated
the explained variance (R2), which was 40%. Additional
adjustment in this model for the several blood pressure-
lowering drugs did not change the relations. Finally, we
excluded patients using comedication, which did not
materially change the results. Also, additional adjustment
for HbA1c did not change the results.4. Discussion
The results of this study on 416 patients with Type 1
diabetes show that BMI, waist circumference, smoking,
HbA1c, TGs, and the use of several blood pressure-lowering
drugs are positively related to daily insulin dose. Age,
female sex, duration of diabetes, HDL cholesterol, physical
activity, and insulin pump use are inversely related to daily
insulin need. Moreover, the use of an insulin pump resulted
in a 14% lower insulin need.
To appreciate the results of this study, some issues need
to be addressed. Because all measurements are performed at
the same point in time in a cross-sectional design, cause–
consequence relations could not be explored. Furthermore,
daily insulin use was determined at one point in time
whereas day-to-day variation in insulin use may be greater
than the variance in several metabolic and clinical variables,
including the prescription of medication. This might have
led to some misclassification, which is assumed to attenuate
the associations under study.
Insulin resistance is associated with the need for higher
insulin doses (Henry et al., 1993; Yki-Jarvinen et al., 1997).
The independent effect of bodyweight and TG levels on daily
insulin dose is in line with studies suggesting that these are
markers of insulin resistance and are, therefore, associatedwith higher insulin use. Our findings for HDL cholesterol
agree with this view. Patients with Type 1 diabetes may also
suffer from the metabolic syndrome, which is sometimes
referred to as bdouble diabetesQ (Libman & Becker, 2003).
Furthermore, it is well known that intensified insulin treat-
ment may result in weight gain (Diabetes Care, 2001), which,
on the other hand, may partly explain our findings.
Some of our findings on the impact on insulin need of
blood pressure-lowering drugs agree with previous reports
(Luna & Feinglos, 2001). h-Blocking agents are known to
slightly deteriorate glucose metabolism (Mills & Horn,
1985; Wicklmayr, Rett, Dietze, & Mehnert, 1990), probably
through reducing peripheral insulin sensitivity (Jacob et al.,
1996). Our findings show a borderline significant relation
between h-blocking agents and insulin use. Diuretics,
especially thiazide diuretics, may also cause glucose into-
lerance (Helderman et al., 1983), primarily through the re-
duction in total body potassium and subsequent decreased
insulin secretion. To our knowledge, this is the first study to
show that the use of thiazide diuretics is positively related to
daily insulin use in Type 1 diabetes (difference of 10.4 U,
P=.01; Table 2).
Furthermore, we found that calcium-channel antagonists
were positively related to daily insulin use (difference of
12.7 U, P=.02; Table 2); however, this is in contrast with
findings by other investigators. Published work suggests
that at hemodynamically active doses, calcium antagonists
do not interfere with glucose tolerance (Collins, Cullen, &
Feely, 1987). The relation of calcium antagonists and insulin
sensitivity or glucose metabolism is less clear.
The relation of most of the antihypertensive drugs with
daily insulin use was more pronounced in patients with a
BMI V25.2 (Table 3). This supports the hypothesis that
these drugs induce insulin resistance, an effect that may be
more evident in patients with a normal BMI, thus with less
insulin resistance. Evidence sustaining the theory of drug-
induced insulin resistance is to be found in the results
obtained from the multivariate model (Table 4) built with
several determinants of the metabolic syndrome, in which
additional adjustment for the blood pressure-lowering drugs
did not change the relations. This may well be explained by
the causal relationship between determinants of insulin
resistance and antihypertensive drugs.
An alternative explanation for an association between
daily insulin need and blood pressure-lowering drugs would
be the well-documented relation of blood pressure levels with
components of the metabolic syndrome that, as indicated
above, may well be present in some patients with Type 1
diabetes. Finally, a relation between antihypertensive drugs
and insulin use could result from bconfounding by indicationQ
(Grobbee & Hoes, 1997). As higher insulin use is related to
worse control and increased risk of complications, these
patients may well need using blood pressure-lowering
medication for that reason. However, additional adjustment
for HbA1c levels did not change the relations we found. This
argues against the hypothesis of bconfounding by indication.Q
M.J. Muis et al. / Journal of Diabetes and Its Complications 20 (2006) 356–360360Chronic cigarette smoking is associated with increased
insulin resistance and could, therefore, lead to a higher
insulin need (Targher et al., 1997). This has also been shown
in experimental studies where cigarette smoking acutely
impaired insulin action (Attvall, Fowelin, Lager, Von
Schenck, & Smith, 1993; Frati, Iniestra, & Ariza, 1996).
Another study found a significant improvement in HbA1c
levels (0.7% decrease) after smoking cessation in 34
subjects with diabetes (Gunton, Davies, Wilmshurst,
Fulcher, & McElduff, 2002). These findings are in line
with those of our study.
A reduced need for insulin in patients using an insulin
pump for continuous subcutaneous insulin infusion (CSII) is
evident. It is known that the use of CSII decreases the
amount of daily insulin dose by at least 14% (Pickup,
Mattock, & Kerry, 2002). In our study, we found a
difference of 9.3 U (18.5%) of the mean daily insulin
dose between patients using and those not using CSII.
Age and duration of diabetes were inversely related to
insulin need (Fig. 1). The relation of age with daily insulin
use is most likely caused by selective nonresponse. Patients
with a higher insulin dose have possibly an increased risk of
acquiring diabetic complications and will get disabling
diseases at an earlier age.
Physical exercise is known to increase insulin sensitivity
and decrease insulin need (Kemmer, 1992; Peirce, 1999). In
our study, this association was only significant after adjust-
ment for weight, which may indicate that body weight is a
stronger determinant of insulin use than physical activity.
Another explanation may be that patients with Type 1
diabetes do more easily gain weight than get exercise.
In conclusion, we found that several components of the
metabolic syndrome, such as high TGs, low HDL choles-
terol, and increased BMI, are positively related to daily
insulin use in Type 1 diabetes. Furthermore, our results
show that decreased physical activity, smoking, and the use
of antihypertensive drugs are associated with an increased
insulin need. The findings of our study suggest that the
presence of insulin resistance in Type 1 diabetes plays a key
role in determining daily insulin need.References
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